期刊文献+

c-myc、HIF-1α在骨巨细胞瘤组织中的表达及其与临床、生物学行为的关系 被引量:1

下载PDF
导出
摘要 目的探讨c-myc、缺氧诱导因子-1α(HIF-1α)在骨巨细胞瘤组织中的表达及其与临床、生物学行为的关系。方法选择80例骨巨细胞瘤患者的手术切除标本,采用免疫组化法检测其瘤组织中的c-myc、HIF-1α表达,分析其与患者临床病理参数、Campanacci影像学分期及预后的关系。结果 80例患者瘤组织中的c-myc、HIF-1α阳性表达率分别为55%、50%,Campanacci影像学分期越高,表达阳性率越高(P<0.05);HIF-1α阳性表达强度与微血管密度、肿瘤预后密切相关(P均<0.01)。结论 c-myc、HIF-1α在骨巨细胞瘤组织中的表达与其恶性进展及复发有关,二者在促进其进展中可能发挥协同作用,可作为评估其生物学行为和判断预后的重要指标。
作者 马琨 郭建刚
出处 《山东医药》 CAS 2014年第5期76-78,共3页 Shandong Medical Journal
  • 相关文献

参考文献12

  • 1Chen C, Cai S, Wang G, et al. c-Myc enhances colon cancer cell- mediated angiogenesis through the regulation of HIF-1 a [ J ]. Bio- chem Biophys Res Commun, 2013,430 ( 2 ) :505-511.
  • 2Kim YJ, Lee HJ, Kim TM, et al. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor lc [J]. IntJCancer, 2013,132(1) :29-41.
  • 3祁玉娟,李积德,赵君慧,等.c-myc、HIF-1a和VEGF在高海拔地区乳腺癌的表达及临床意义[J].2010,25(1):32-36.
  • 4Fletcher CDM, Unni KK, Mertcns F. Pathology and genetics of tumors of soft tissue and bone [ M ]. Lyon: IARC Press, 2002 : 210.
  • 5李灼日,吴金术,毛先海,田秉璋.C-myc、P16和Bc1-2蛋白在胆管癌中表达及意义[J].中国现代医学杂志,2006,16(22):3427-3430. 被引量:9
  • 6林称意,郭家龙,左顺庆,张军,谢斌生.PTTG与c-myc在食管癌中的表达及其相关性[J].肿瘤防治研究,2009,36(5):415-418. 被引量:7
  • 7刘金洋,李康华,黎岳南.Fas、Bcl-2、C-myc蛋白在骨肉瘤和良性骨肿瘤中的表达及意义[J].实用肿瘤杂志,2006,21(1):59-60. 被引量:4
  • 8Wang Y, Wan C, Deng L, et al. The hypoxia-inducible factor al- pha pathwaycouples angiogenesis to osteogenesis during skeletal de- velopment [ J ]. J Clin Invest, 2007,117 ( 6 ) : 1616-1626.
  • 9Li H, Yang BB. Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2 [ J]. Oncotarget, 2012,3 ( 12 ) : 1653-1656.
  • 10Zhang J, Sattler M, Tonon G, et al. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-lalpha-dependent pathway in multi- ple myeloma[ J]. Cancer Res, 2009,69(12) :5082-5090.

二级参考文献30

  • 1丛佳,汪洪毅.垂体瘤转化基因(PTTG)的研究进展[J].肿瘤防治研究,2005,32(8):522-524. 被引量:4
  • 2Dorfman HD,Czerhiak B.Bone Cancers [J].Cancer,1995,75(1):203-210.
  • 3Nagata S,Gdstein P.The Fas death factor [J].Science,1995,267(5203):1447-1449.
  • 4Vaux DL,Cory S,Adems JM,et al.Bcl-2 genes promotes heamopoietic cells survival and cooperates with C-myc to immortalize pro-B-cell [J].Nature,1998,335(6189):440-442.
  • 5Hamada T,Komiva S,Yano H,et al.Moduletion of fas-mediated apoptosis in osteosarcoma cell lines [J].Int J Oncol,1999,15(16):1125-1131.
  • 6Yu R, Melmed S. Pituitary tumor transforming gene: an update [J]. Front Horm Res, 2004,32(1) :175-178.
  • 7Robson S, Pelengaris S, Khan M, et al. c- myc and downstream targets in the pathogenesis and treatment of cancer [J]. Recent Patents Anticancer Drug Discov, 2006 , 1 (3): 305-326.
  • 8Bradshaw C, Kakar SS. Pituitary tumor transforming gene:an important gene in normal cellular functions and tumorigenesis[J]. Histol Histopathol, 2007, 22(2):219-226.
  • 9Donangelo I, Melmed S, Solbach C, et al. Pituitary tumortransforming gene (PTTG): a novel target for anti-tumor therapy[J]. Anticancer Res, 2005,25 (1) : 121-125.
  • 10Stella Pel, Mike Kh, Gerard E, et al. c-myc: More than just a matter of life and death[J]. Nature Reviews Cancer, 2002,904 (2) : 764-776.

共引文献27

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部